Evidence map›Paper›PMID 36566098›Full record

Observational studyResearch in social & administrative pharmacy : RSAP2023

Technology targeting immunocompromised patients for COVID-19 vaccine in community pharmacies.

Grace E LaFleur, Andrew G Azzi, Scott M Schimmel, Mitchell S Howard

Abstract readObservational Study
In one paragraph

Observational study in Research in social & administrative pharmacy : RSAP, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Grace E LaFleurThe University of Toledo College of Pharmacy and Pharmaceutical Sciences, 3000 Arlington Ave. Mail Stop 1013, Toledo, OH, 43614, USA; The Kroger Co., 2257 N Holland Sylvania Rd, Toledo, OH, 43615, USA.
Andrew G AzziThe Kroger Co., 2257 N Holland Sylvania Rd, Toledo, OH, 43615, USA.
Scott M SchimmelThe Kroger Co., 2257 N Holland Sylvania Rd, Toledo, OH, 43615, USA.
Mitchell S HowardThe University of Toledo College of Pharmacy and Pharmaceutical Sciences, 3000 Arlington Ave. Mail Stop 1013, Toledo, OH, 43614, USA. Electronic address: Mitchell.Howard@utoledo.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMedication targeting by community pharmacists may assess medical history of patients for recommendation of clinical services through review of their prescription history. Previous studies have implemented medication targeting to identify patients eligible for vaccine recommendations. Targeting of immunosuppressing medications may impact the rate of third primary doses of COVID-19 vaccine administered to immunocompromised patients.

objectivesThe primary objective was to determine the impact of medication targeting on the rate of third primary doses of COVID-19 vaccine given to immunocompromised patients.

methodsThis observational, retrospective cohort study occurred within one division of a large community pharmacy chain. Included patients were greater than 18 years of age with record of at least one immunosuppressing medication dispensed one year prior to study enrollment and 2 primary COVID-19 vaccine doses in the pharmacy dispensing software. An intervention for pharmacist recommendation of a third primary dose of COVID-19 vaccine was automatically loaded into their prescription profiles. The proportion of patients with completed interventions and confirmation of third dose administration was collected with demographic characteristics.

resultsThe pharmacy dispensing software identified 1670 interventions through medication targeting, though 69 interventions met criteria for study inclusion. Baseline characteristics of the included population were a mean age of 51.8 years of primarily female sex (69.6%) and Caucasian race (78.3%). Third primary COVID-19 vaccine dose administration and completed pharmacist recommendation was recorded for 2 (2.9%) patients.

conclusionMedication targeting identified immunocompromised patients for the recommendation of a third primary dose of COVID-19 vaccine. Improved specification for targeting of dosing regimen and route of administration may result in greater accuracy of appropriate recommendations identified.

Indexed as

Community Pharmacy ServicesCOVID-19PharmaciesCOVID-19 VaccinesFemaleHumansMiddle AgedPharmaceutical PreparationsPharmacistsRetrospective StudiesTechnologyCOVID-19 VaccinesPharmaceutical PreparationsCommunityImmunizationMedication targetingTechnology

Identifiers

PMID36566098
PMCPMC9715457

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.